G

Guobang Pharma Ltd
SSE:605507

Watchlist Manager
Guobang Pharma Ltd
SSE:605507
Watchlist
Price: 19.16 CNY -0.83% Market Closed
Market Cap: 10.7B CNY

Wall Street
Price Targets

Price Targets Summary
Guobang Pharma Ltd

There are no price targets for Guobang Pharma Ltd.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Guobang Pharma Ltd Competitors:
Price Targets
000513
Livzon Pharmaceutical Group Inc
8% Upside
NKTR
Nektar Therapeutics
525% Upside
600285
Henan Lingrui Pharmaceutical Co Ltd
33% Upside
ALKEM
Alkem Laboratories Ltd
9% Upside
ARVN
Arvinas Inc
259% Upside
MYX
Mayne Pharma Group Ltd
7% Upside
PFE
Pfizer Inc
30% Upside
EYPT
EyePoint Pharmaceuticals Inc
428% Upside

Revenue
Forecast

Revenue Estimate
Guobang Pharma Ltd

For the last 5 years the compound annual growth rate for Guobang Pharma Ltd's revenue is 9%. The projected CAGR for the next 3 years is 11%.

9%
Past Growth
11%
Estimated Growth
Estimates Accuracy
-9%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Guobang Pharma Ltd

Operating Income forecast
is not available for
Guobang Pharma Ltd

Net Income
Forecast

Net Income Estimate
Guobang Pharma Ltd

For the last 5 years the compound annual growth rate for Guobang Pharma Ltd's net income is 20%. The projected CAGR for the next 3 years is 17%.

20%
Past Growth
17%
Estimated Growth
Estimates Accuracy
-16%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Guobang Pharma Ltd's stock price target?
Not Available

Guobang Pharma Ltd doesn't have any price targets made by Wall Street professionals.

What is Guobang Pharma Ltd's Revenue forecast?
Projected CAGR
11%

For the last 5 years the compound annual growth rate for Guobang Pharma Ltd's revenue is 9%. The projected CAGR for the next 3 years is 11%.

What is Guobang Pharma Ltd's Net Income forecast?
Projected CAGR
17%

For the last 5 years the compound annual growth rate for Guobang Pharma Ltd's net income is 20%. The projected CAGR for the next 3 years is 17%.

Back to Top